Organic Active Ingredients TRIZ Cases

Heteroaromatic compounds modulate dopamine D1 receptors to treat schizophrenia and Parkinson's disease.

Specific aminooxazoline structures achieve selective TAAR1 binding while minimizing adrenergic receptor interaction to reduce cardiovascular side effects.

Urea carbonyl linkers enable flexible multi-drug loading on PEG carriers, resolving the trade-off between circulation time and composition versatility.

A small molecule inhibitor targets TNF-α signaling pathways to reduce inflammatory symptoms in ulcerative colitis models.

Parallel conduit design reduces flow rate dependence, ensuring uniform dose delivery across varying patient inhalation profiles.

Oxopyridinyl compounds selectively increase correctly folded Z A1AT secretion, resolving misfolding issues that limit current augmentation therapies.

Antisense oligonucleotides inhibit Androgen Receptor expression to prevent muscle atrophy and motor neuron degeneration in Kennedy's Disease.

Glucuronide metabolites shift absorption from the colon to the stomach via sulfated starch retention, minimizing interindividual variation in drug levels.

A selective S1P1 agonist protects renal function by maintaining endothelial barrier integrity.

Soluble alkaline phosphatase catalyzes pyrophosphate hydrolysis to improve spinal fusion reliability and reduce pseudoarthrosis rates.

Nitrogen inert gas deoxygenation reduces subvisible particle formation in noradrenaline solutions by maintaining low oxygen levels without antioxidants.

Novel bicyclic pyrazole compounds target Slo-1 calcium channels in nematodes, bypassing macrocyclic lactone resistance mechanisms.

Anti-CGRP antibodies increase peripheral and hepatic glucose utilization to resolve insulin resistance.

Pyrimidine derivatives potentiate the hMrgX1 receptor to treat chronic pain conditions.

A swallowable capsule deploys tissue-penetrating members to advance therapeutic agents directly into the intestinal wall.

Optimized excipient concentrations preserve supercoiled DNA during freeze drying.

A calcium carbonate and citrate salt composition induces rapid blood coagulation.

A hydrophilic polymer conjugated with an opioid receptor antagonist creates a molecule that targets peripheral receptors.

An albumin binding domain shields standard nucleic acid sequences from enzymatic degradation while maintaining broad utility.

Benzimidazole-based imidazolidine derivatives resolve insufficient potency and limited blood-brain barrier penetration of prior art inhibitors.

Optimized shTACE sequences paired with nonviral carriers resolve yield and stability issues to treat inflammatory diseases.

Modular benzimidazole compounds achieve selective TAK1 inhibition by optimizing substituent patterns to reduce off-target MAP2K effects.

Substituted quinoline derivatives target cancer stem cells to overcome drug resistance while minimizing toxicity to normal tissues.

A new process uses 1-halo-4-propylhept-3-ene in a Grignard reaction to synthesize delmopinol with higher purity.

Solvent extraction removes lectins from fermented wheat germ, enabling versatile administration routes while maintaining high active ingredient concentration.

1,2,5-Oxadiazole derivatives inhibit indoleamine 2,3-dioxygenase to reverse immunosuppression and enhance antitumor T-cell activation.

An acetic acid and sodium acetate complex stabilizes poorly soluble drugs in adhesive bases, preventing crystallization during solvent removal.

A nitrogen-containing fused heterocyclic compound inhibits the SHP2 enzyme through specific molecular structure optimization.

Galactose-conjugated RNAi agents bind asialoglycoprotein receptors to deliver therapeutic oligonucleotides into liver cells.

Deuterium incorporation retards racemization and alters metabolic pathways to reduce unwanted metabolites in angiogenesis therapeutics.

Replacing arylsulfonamide groups with phenylacetic acid cores reduces hepatic toxicity while maintaining therapeutic potency.

Segmented quinoline derivatives deliver targeted cytotoxicity to resistant tumor cells while minimizing toxicity to normal tissues.

Glucosamine-functionalized oligonucleotide conjugates enable precise cellular uptake in target organs.

Combines Bcl-2 and MDM2 inhibitors to overcome single-drug resistance while minimizing toxicity.

Specific binder-to-active ratios resolve interference between tablet formability and chromatographic analysis of related substances.

Formula I compounds inhibit KRAS activity via imidazole or triazole cores, addressing limited therapeutic options for mutant cancers.

Oral paclitaxel combined with a P-glycoprotein inhibitor achieves therapeutic blood levels.

Formula I compounds target pyrimidine synthesis to eliminate leukemic stem cells and overcome chemotherapy resistance.

Targeting conserved NS4B proteins, spirotriazolopyridine analogues overcome limited vaccine efficacy and safety issues.

Formula I triazole compounds inhibit NR2B receptor activity through selective binding mechanisms.

Specific beta-glucan parameters raise intestinal viscosity, reducing serum LDL cholesterol variability without complex extraction processes.

Merges ketotifen with NSAIDs like naproxen to address limited treatment options by reducing SARS-CoV-2 viral load.

Segmenting single targets into multi-specific antibody cocktails overcomes tumor heterogeneity and normal cell damage.